1. Academic Validation
  2. Design and synthesis of poly ADP-ribose polymerase-1 inhibitors. 2. Biological evaluation of aza-5[H]-phenanthridin-6-ones as potent, aqueous-soluble compounds for the treatment of ischemic injuries

Design and synthesis of poly ADP-ribose polymerase-1 inhibitors. 2. Biological evaluation of aza-5[H]-phenanthridin-6-ones as potent, aqueous-soluble compounds for the treatment of ischemic injuries

  • J Med Chem. 2003 Jul 3;46(14):3138-51. doi: 10.1021/jm030109s.
Dana Ferraris 1 Yao-Sen Ko Thomas Pahutski Rica Pargas Ficco Larisa Serdyuk Christina Alemu Chadwick Bradford Tiffany Chiou Randall Hoover Shirley Huang Susan Lautar Shi Liang Qian Lin May X-C Lu Maria Mooney Lisa Morgan Yongzhen Qian Scott Tran Lawrence R Williams Qi Yi Wu Jie Zhang Yinong Zou Vincent Kalish
Affiliations

Affiliation

  • 1 Guilford Pharmaceuticals Inc, 6611 Tributary Street, Baltimore, Maryland 21224, USA. ferraisd@guildfordpharm.com
Abstract

A series of aza-5[H]-phenanthridin-6-ones were synthesized and evaluated as inhibitors of poly ADP-ribose polymerase-1 (PARP-1). Inhibitory potency of the unsubstituted aza-5[H]-phenanthridin-6-ones (i.e., benzonaphthyridones) was dependent on the position of the nitrogen atom within the core structure. The A ring nitrogen analogues (7-, 8-, and 10-aza-5[H]-phenanthridin-6-ones) were an order of magnitude less potent than C ring nitrogen analogues (1-, 2-, 3-, and 4-aza-5[H]-phenanthridin-6-ones). Preliminary stroke results from 1- and 2-aza-5[H]-phenanthridin-6-one prompted structure-activity relationships to be established for several 2- and 3-substituted 1-aza-5[H]-phenanthridin-6-ones. The 2-substituted 1-aza-5[H]-phenanthridin-6-ones were designed to improve the solubility and pharmacokinetic profiles for this series of PARP-1 inhibitors. Most importantly, three compounds from this series demonstrated statistically significant protective effects in rat models of stroke and heart ischemia.

Figures
Products